{'fraction_non_alphanumeric': 0.025044722719141325, 'fraction_numerical': 0.005366726296958855, 'mean_word_length': 6.0886075949367084, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Rethinking recycling nucleoside reverse transcriptase inhibitors in HIV treatment: learning from dual therapy studies.

Although a large number of studies have addressed firstline antiretroviral therapy in HIV-infected patients, less has been done to investigate patient management following treatment failure, particularly in countries with limited resources [1]. Genotypic resistance testing after failure is recommended to build the new regimen, possibly combining at least two active drugs, to maximize the likelihood of regaining viral suppression [2–4].